About the University of Birmingham
The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, educators and more than 40,000 students from over 150 countries. The University of Birmingham collaborates with industry to drive investment into research and innovation that changes how the world works. Find out more: https://www.birmingham.ac.uk/collaborate/business-engagement
University of Birmingham Press Office: pressoffice@contacts.bham.ac.uk
About Shionogi & Co. Ltd.
Shionogi & Co., Ltd. is a 147-year-old global, research-driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology. Shionogi’s research and development currently target two therapeutic areas: infectious diseases, and pain/CNS disorders. For more information on Shionogi & Co., Ltd., please visit: https://www.shionogi.com/global/en.
SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html
Shionogi Europe Press Office: pressoffice@shionogi.eu
About the University of Warwick
Founded in 1965, the University of Warwick is a world-leading institution known for its commitment to era-defining innovation across research and education. A connected ecosystem of staff, students and alumni, the University fosters transformative learning, interdisciplinary collaboration and bold industry partnerships across state-of-the-art facilities in the UK and global satellite hubs. Here, spirited thinkers push boundaries, experiment and challenge convention to create a better world.
A note on forward-looking statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
References
1 The Royal Mencap Society. How common is learning disability in the UK? [Internet]. 2024 [cited 2025 Nov 21]. Available from: https://www.mencap.org.uk/learning-disability-explained/research-and-statistics/how-common-learning-disability
2 Russell G, Mandy W, Elliott D, White R, Pittwood T, Ford T. Selection bias on intellectual ability in autism research: a cross-sectional review and meta-analysis. Mol Autism. 2019;10:9.
3 Shields RH, Kaat AJ, McKenzie FJ, Shashi V, Hooper SR, Petersen AJ, et al. Validation of the NIH Toolbox Cognitive Battery in children and adolescents with intellectual disability. J Intellect Disabil Res. 2020;64(7):567-580.
4 Laverty C, Richards C. Promoting accessible research for children with intellectual disabilities; lessons learnt from adaptations through the COVID-19 pandemic. J Intellect Disabil Res. 2025 Oct 3;1-8. doi:10.1111/jir.70055.